Answers are grounded in this paper and cite their sources.
Epidemiological evidence points to a connection between inflammation and a predisposition for the development of cancer. Several pro-inflammatory gene products have been identified that lead to variations in the production and concentration of inflammatory proteins. A case-control study was conducted in chemokine and chemokine receptor genes (MCP-1 A-2518G and CCR2-V64I) to elucidate the possible role of these SNPs as risk factors in urinary bladder cancer (UBC) development. Using the polymerase chain reaction-restriction fragment length polymorphism approach, we investigated the genotype distribution of 120 bladder cancer patients in comparison with 155 cancer-free controls from the same geographical region. Significant differences were observed in the distribution of genotypes in MCP-1 A-2518G between the control and bladder cancer patients (0.36 vs 0.47; p=0.000). Homozygous variant GG frequency of MCP-1 A-2518G in cases was found to be 20% as against 5.1% in controls (p<0.05). No significant association was found in CCR2-V64I genotypes (p = 0.09) between the controls and patients with the frequency of homozygous variant (64I) being 15% and 20% (0.15 vs. 0.20) respectively. Interestingly, CCR2-V64I heterozygote (wt/64I+64I) frequencies were significantly increased in the higher grades/stages of bladder cancer patients (p< 0.05). Based on above mentioned results, we conclude that the MCP-1 -2518A/G polymorphism is associated with genetic susceptibility to the risk for bladder cancer.
No takes yet. Share an insight, caveat, or question.
Pandith et al. (2012) studied this question.
Synapse has enriched 3 related papers. Consider them for comparative context: